|
| Status |
Public on Mar 31, 2016 |
| Title |
Gene expression profiling of primary HER2-positive breast cancers treated with neoadjuvant trastuzumab |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
Trastuzumab, a humanized monoclonal antibody directed to the HER2 protein, is the standard-of-care treatment for patients with HER2 positive breast cancer, reducing the risk of relapse and death in patients. Nonetheless, some patients do not benefit from this treatment, underscoring the need to identify patients for whom chemotherapy + trastuzumab is adequate versus patients requiring additional drugs. The series comprised 24 incisional biopsies of breast carcinomas derived from patients that received neoadjuvant trastuzumab based therapy.
|
| |
|
| Overall design |
Gene expression profiling was performed using RNA from frozen core biopsies from 24 patients with primary HER2-positive (HER2+) tumors treated with neoadjuvant chemotherapy and trastuzumab.
|
| |
|
| Contributor(s) |
De Cecco L |
| Citation(s) |
26334217 |
| |
| Submission date |
Oct 14, 2014 |
| Last update date |
Dec 22, 2017 |
| Contact name |
Loris De Cecco |
| E-mail(s) |
loris.dececco@istitutotumori.mi.it
|
| Organization name |
IRCSS Istituto Nazionale Tumori
|
| Street address |
via Venezian 1
|
| City |
Milan |
| ZIP/Postal code |
20133 |
| Country |
Italy |
| |
|
| Platforms (1) |
| GPL14951 |
Illumina HumanHT-12 WG-DASL V4.0 R2 expression beadchip |
|
| Samples (24)
|
|
| Relations |
| BioProject |
PRJNA263833 |
Less...
More...